Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
76.29
-5.26 (-6.45%)
Mar 3, 2025, 4:00 PM EST - Market closed
Insmed Revenue
In the year 2024, Insmed had annual revenue of $363.71M with 19.17% growth. Insmed had revenue of $104.44M in the quarter ending December 31, 2024, with 24.79% growth.
Revenue (ttm)
$363.71M
Revenue Growth
+19.17%
P/S Ratio
36.78
Revenue / Employee
$286,158
Employees
1,271
Market Cap
13.81B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
INSM News
- 6 days ago - Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says - Benzinga
- 7 days ago - Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis - PRNewsWire
- 11 days ago - Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update - PRNewsWire
- 20 days ago - Insmed To Present at March 2025 Investor Conferences - PRNewsWire
- 21 days ago - Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025 - PRNewsWire
- 24 days ago - Insmed: Priority Review For Brensocatib Cements (Limited) Upside Opportunity - Seeking Alpha
- 24 days ago - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire